Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 8/20 | 0.46 |
| ▸ | SLC6A11 | P48066 | 4/20 | 0.42 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.37 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27177312 | 1.00 | KIF11 (0.46) | KIF11SLC6A11SLC6A1KCNH2MEN1 | |
| SCHEMBL27177314 | 0.88 | KIF11 (0.52) | KIF11SLC6A1 | |
| SCHEMBL9537662 | 0.87 | KIF11 (0.47) | KIF11SLC6A11SLC6A1KCNH2MEN1 | |
| SCHEMBL27177311 | 0.86 | KIF11 (0.46) | KIF11SLC6A11SLC6A1KCNH2MEN1 | |
| SCHEMBL7165376 | 0.86 | KIF11 (0.46) | KIF11SLC6A11SLC6A1KCNH2MEN1 | |
| SCHEMBL2985182 | 0.82 | KIF11 (0.49) | KIF11SLC6A11SLC6A1KCNH2MEN1 | |
| SCHEMBL13658487 | 0.82 | KIF11 (0.47) | KIF11SLC6A11SLC6A1KCNH2 | |
| SCHEMBL16021678 | 0.81 | KIF11 (0.46) | KIF11SLC6A11SLC6A1KCNH2MEN1 | |
| SCHEMBL30770594 | 0.80 | KIF11 (0.43) | KIF11SLC6A11SLC6A1KCNH2MEN1 | |
| SCHEMBL3997667 | 0.80 | KIF11 (0.48) | KIF11SLC6A11SLC6A1KCNH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4341270-A1 | CHEMICAL PHOSPHORYLATION REAGENTS, PREPARATION, AND THEIR USES | Olix US, Inc. (US) | 2024-03-27 | — | — | EP | claimed |
| EP-4341270-A1 | CHEMICAL PHOSPHORYLATION REAGENTS, PREPARATION, AND THEIR USES | Olix US, Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4143316-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2023-03-08 | — | — | EP | disclosed |
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2022-06-14 | — | — | US | disclosed |
| WO-2021220053-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2021-11-04 | — | — | WO | disclosed |
| US-20210330810-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | KIF11 1884/4885SLC6A11 4742/4885SLC6A1 4609/4885 |
| US-20210330810-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | NCL, NSUN3, POLN | KIF11 1884/4885SLC6A11 4742/4885SLC6A1 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.